The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two decades. Historically, therapeutic strategies primarily focused on ...

Our results indicate that there is a connection between the administration of TNF-α blockers in the population and the adverse events of thrombosis, which is in line with previous research results.

Nordstrom, et al., “Cancer Risk with Tumor Necrosis Factor Alpha (TNF) Inhibitors: Meta-Analysis of Randomized Controlled Trials of Adalimumab, Etanercept, and Infliximab Using Patient Level Data,” ...

If you have sacroiliitis from a spondyloarthritis such as ankylosing spondylitis, medications known as TNF-alpha blocker drugs may be beneficial. Some potential options include: Enbrel (etanercept) ...

Molecular-guided decision-making improves disease control and remission in the treatment of IBD with anti-TNF therapy, however, application to other therapies is questioned.

Here's a new summary of all the drugs in the pipeline currently being evaluated for the treatments of vasculitis.

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA ® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management ...

Infliximab is an intravenous (IV) anti-TNF-α therapy, in which its safety and efficacy is supported by nearly 20 years of real-world experience. Whilst infliximab is proven to be effective in ...

announced that data from the Phase 2a clinical trial of its oral TNF-alpha inhibitor drug candidate isomyosamine was presented last week in a podium session at the peer-reviewed 15th International ...

Among patients who were initiated on the tumor necrosis factor (TNF) inhibitor infliximab (Remicade), 55.3% of those receiving molecular medicine-informed guidance with insights from a real-time ...